Drugs / TLD1433
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03053635 | Dec 2016 → Aug 2018 | urinary tract non-invasive transitional cell neoplasm | Theralase® Technologies Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2015-01-29 | Theralase® Technologies Inc. | Results Theralase’s Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference theralase.com ↗
Theralase’s latest scientific research has shown that TLD-1433 directly bound to transferrin results in significant enhancements of TLD1433’s biomedical properties and its efficacy in the destruction of cancer cells: |
| 2014-12-23 | Theralase® Technologies Inc. | Results Theralase Reports Results of PDC Therapy of Bladder Cancer in Orthotopic Rat Model theralase.com ↗
From the visual, clinical inspection, TLD1433 appeared to localize to specific regions of the bladder, indicating that TLD1433 accumulated in damaged and tumour urothelium |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-01-29 | Theralase® Technologies Inc. | Theralase’s Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference theralase.com ↗ |
| 2014-12-23 | Theralase® Technologies Inc. | Theralase Reports Results of PDC Therapy of Bladder Cancer in Orthotopic Rat Model theralase.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLD1433 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03053635 ↗ |